Peptide library
Brain

Dihexa

Angiotensin IV analog studied in synaptogenesis research.

Preclinical OnlyEmerging Research

Evidence Level

Emerging

Mechanism5/10
Safety Clarity3/10
Research Popularity6/10

Research Type

AnimalIn vitro

/ System Mapping

Where this compound appears in research pathways

Research-only note: This mapping is educational and does not represent a treatment protocol.

/ 01

Overview

Angiotensin IV analog studied in synaptogenesis research.

/ 02

Mechanism of Action

Studied for HGF/c-Met signaling and dendritic spine formation.

/ 03

Research Applications

Cognitive enhancement and neural plasticity research.

Studied for, research explores, preclinical models suggest, clinical studies have investigated.

/ 04

Studied Research Contexts

AnimalIn vitro

/ 05

Studied Research Dosing Ranges

Limited public data on dosing ranges across research models.

Dosing varies by study design and is not a recommendation for human use.

/ 06

Potential Adverse Effects Reported in Research

Adverse effect data is limited. Many compounds in this database lack human safety profiles.

/ 07

Mechanism Deep Dive

Dihexa is an angiotensin IV-derived compound. Preclinical research describes interaction with HGF/c-Met signaling and reported synaptogenic activity in cell and rodent models.

/ 08

Pathway Role

Sits within HGF/c-Met signaling and synaptogenesis pathways in preclinical neural models.

/ 09

Biological Targets

HGF/c-Met signalingSynaptogenesis markersProcognitive signaling networks (preclinical)

/ 10

Research Applications

  • Cognitive function preclinical studies
  • Synaptogenesis mechanism research

/ 11

Evidence Summary

Preclinical evidence only. No established human outcome data.

Evidence Level Rationale

Rated preclinical/emerging due to absence of human controlled trials.

/ 12

Research Observation Timeline

Early Signal Window

Cellular synaptogenic markers within hours to days in vitro

Primary Study Window

Days to weeks in preclinical models

Endpoint Type

Cellular and behavioral preclinical endpoints

Evidence Strength

Preclinical only

No human timeline. Preclinical synaptogenic mechanism only; human timeline not established.

/ 13

Safety & Unknowns

Human safety profile is not characterized in published controlled studies.

/ 14

Research Limitations

Translation from preclinical synaptogenic mechanism to human outcomes is not established.

/ 15

References

References are being curated from peer-reviewed literature.

/ 07

Evidence Score

Mechanism Confidence5/10
Safety Clarity3/10
Research Popularity6/10

Overall Research Confidence

Emerging

Reflects breadth of mechanism, study type, and reproducibility across research literature.

For research and educational purposes only.

Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.